FDA approves Viridian's Lumvoa for thyroid eye disease in both active and chronic disease
Veligrotug produced a proptosis response in 70% of patients with active disease and 57% with chronic disease at week 15.
Veligrotug produced a proptosis response in 70% of patients with active disease and 57% with chronic disease at week 15.